Avicanna (AVCNF) AI Stock Analysis

21 Followers

Avicanna

(Other OTC:AVCNF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Proprietary mix and gross-margin improvementA rising proprietary-product mix can support more differentiated economics and reduce reliance on lower-margin offerings. The accompanying year-over-year margin improvement suggests product mix and commercialization efforts are strengthening the underlying earnings profile, although profitability is not yet established.

Negative Factors

Persistent losses and negative cash generationPersistent operating and free-cash-flow deficits limit the company’s ability to fund growth internally and leave execution dependent on reaching sustainable break-even. Ongoing losses also reduce financial flexibility, even though recent adjusted EBITDA improvement shows some progress toward better operating performance.

Avicanna (AVCNF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $8.08M
Dividend Yield: ―
Average Volume (3M): 84.89K
Price to Earnings (P/E): -2.6
Beta (1Y): 1.42
Revenue Growth: 0.74%
EPS Growth: -139.80%
Country: US
Employees: 112
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Avicanna Business Overview & Revenue Model

Company Description

Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health ma...

Avicanna Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:5.00%|Next Earnings Date:May 25, 2020

Earnings Call SentimentPositive

The call was broadly positive. Management highlighted the first positive adjusted EBITDA quarter, improving operating results, stronger gross margins year-over-year, reduced expenses, improved working capital, growth in proprietary and international revenue, the launch and expansion of the QUIX portfolio, and progress in clinical, pharmaceutical, and international initiatives. These positives were tempered by a 10% year-over-year revenue decline, lower gross profit, sequential gross-margin compression, negative operating cash flow, the impact of Veterans Affairs Canada reimbursement changes, licensing revenue variability, debt obligations, and the company's low market valuation.

Positive Updates

Ten-Year Milestone and Expanded Business Platform

Avicanna will reach its 10-year anniversary next week. The company has evolved into an international biopharmaceutical company with 68 commercial SKUs, 1 pharmaceutical product, several clinical programs, and established international commercial operations.

Negative Updates

Year-over-Year Revenue Decline

Q3 revenue declined 10% year-over-year to $5.7 million, primarily due to Veterans Affairs Canada reimbursement changes that reduced reimbursement for veteran patients by 29% effective April 1, along with lower licensing revenue.

Company Guidance

For Q4, management expects to continue the cost discipline, launch further QUIX SKUs across the Canadian market, improve the MyMedi percentage of sales, and generate “some early signals of international revenue growth”; it expects the majority of recent G&A savings to be recurring into Q4 and going into next year, expects to file an SR&ED claim every year going forward, and expects the Avicanna share of MyMedi sales to trend towards “40% to even 50% of the sales.” Management expects further SKU launches, margin efficiencies, and signals of growth going into Q4, early signals from SMGH this year and next year, significant pharmaceutical milestones going into 2027, and U.S. rescheduling “towards the end of this year or early next year.”

Avicanna Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

AVCNF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:INNO	54Neutral	CAD 8.19M	-6.15	-19.37%	―	-19.20%	42.54%
TSE:LABS	53Neutral	CAD 25.63M	-5.60	-13.79%	―	-6.74%	43.54%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:CWEB	42Neutral	CAD 65.11M	-0.85	-285.96%	―	-7.77%	-52.56%
TSE:PCLO	42Neutral	CAD 9.34M	-2.67	28.59%	―	0.90%	57.73%
TSE:CRDL	41Neutral	CAD 173.75M	-4.24	-180.13%	―	―	29.34%

* Healthcare Sector Average

Performance Comparison

AVCNF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
AVCNF	Avicanna Inc	0.06	-0.11	-63.79%
TSE:CWEB	Charlotte's Web Holdings (OTC)	0.27	0.14	112.00%
TSE:LABS	Medipharm Labs (Otc)	0.07	0.00	0.00%
TSE:PCLO	Pharmacielo	0.05	0.00	6.67%
TSE:CRDL	Cardiol Therapeutics Inc.	1.47	0.03	2.08%
TSE:INNO	Innocan Pharma Corporation	1.82	-14.68	-88.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Avicanna AI Stock Analysis